(Hypertension. 2001;38:1038.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
From the Department of Bioengineering, Rice University (K.T.N., S.R.F., S.G.E., L.V.M.), Houston, Tex; and the Program in Molecular Cardiology, Department of Internal Medicine, University of North Carolina at Chapel Hill (C.P., M.S.R.).
Correspondence to Larry V. McIntire, PhD, Rice University, Department of Bioengineering MS 142, PO Box 1892, Houston, TX 77251-1892. E-mail mcintire{at}rice.edu
| Abstract |
|---|
|
|
|---|
Key Words: muscle, smooth, vascular stress mechanical gene expression thrombin protein kinases oxidative stress
| Introduction |
|---|
|
|
|---|
Many of the effects of thrombin, including inflammation and cell proliferation, are mediated by protease-activated receptor-1 (PAR-1). Furthermore, PAR-1 expression is increased in atherosclerotic and balloon-injured arteries and in arteries of hypertensive animals,1012 indicating its contribution to the development of arterial diseases. We postulated that the PAR-1 gene in VSMCs would be regulated by cyclic strain, on the basis of the important role that PAR-1 plays in controlling VSMC functions and proliferation in vivo.
Cyclic strain (20%) induced PAR-1 mRNA expression, leading to an increase in surface PAR-1 protein and an increase in cell proliferation in response to thrombin. In addition, strain-enhanced PAR-1 expression may be mediated by reactive oxygen species (ROS) through the NADPH oxidase pathway and is negatively regulated through protein kinase C (PKC). We found no evidence that NO synthase, tyrosine kinase, or mitogen-activated protein kinase (MAPK) pathways regulated strain-induced PAR-1 expression. Basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF-AB) have been shown to induce PAR-1 expression.12,13 bFGF and cyclic strain applied together increased PAR-1 expression beyond the increase induced by either stimulus alone; whereas PDGF-AB, when applied to cells concomitantly with cyclic strain, had no additional effect on PAR-1 expression.
| Methods |
|---|
|
|
|---|
Northern Analysis and Flow Cytometry
Total RNA was isolated by using the fast-RNA isolation kit (BIO101) and analyzed as described previously.14 To correct for differences in RNA loading, the signal intensity of PAR-1 for each sample was normalized to GAPDH. For flow cytometry, HASMCs were preincubated with thrombin (4 U/mL, 15 minutes), exposed to 20% cyclic strain for 24 hours, and detached and labeled as previously described.16 The geometric mean fluorescence of each sample (10 000 cells) was calculated as a percentage of matched static controls.
Cell Proliferation in Response to Thrombin
HASMCs were exposed to 20% strain in serum-containing medium for 24 or 48 hours, washed, and incubated in serum-free medium (30 minutes); then thrombin (5 U/mL in serum-free DMEM) was added or not, and cells were further incubated for 24 hours under static conditions and counted (Coulter).
O2- Production
HASMCs were preincubated in serum-containing medium without phenol red (30 minutes, 37°C), and cytochrome c (final concentration, 1 mg/mL) with or without superoxide dismutase (final concentration, 500 U/mL) was added.17 Cells were then exposed to cyclic strain; medium was collected at 0, 20, 40, and 60 minutes; and absorbance was read (550 nm). Equivalent superoxide (O2-) production was estimated by converting the optical density difference between samples with or without superoxide dismutase by using the molar extinction coefficient for cytochrome c: 21x103 (mol/L)-1 · cm-1.
ROS, NO, and Protein Kinase Inhibitors
HASMCs were pretreated (1 hour) with N-acetyl-L-cysteine (NAC, 1 to 20 mmol/L; antioxidant), pyrrolidine dithiocarbamate (PDTC, 50 µmol/L; antioxidant),17 diphenyleneiodonium chloride (DPI, 1 to 20 µmol/L; NADPH oxidase inhibitor),18 indomethacin (10 µmol/L, cyclooxygenase inhibitor), oxypurinol (10 µmol/L, xanthine oxidase inhibitor),17,18 NG-methyl-L-arginine (L-NMMA, 1 mmol/L; NO synthase inhibitor), staurosporine (1 to 20 nmol/L, nonspecific protein kinase inhibitor), Ro 31-8220 (0.1 µmol/L, PKC inhibitor),19 herbimycin A (2.0 µmol/L, tyrosine kinase inhibitor), or PD 098,059 (50 µmol/L, MAPK kinase inhibitor).20 Cells were subjected to 20% strain in the presence of the same inhibitor for 12 hours. In separate experiments, HASMCs were treated with the PKC activator phorbol 12-myristate 13-acetate (PMA, 0.3 µmol/L) for 12 hours.
Effects of Cyclic Strain and Growth Factors
HASMCs were incubated in serum-free medium for 24 hours and then subjected to cyclic strain alone, 15 ng/mL bFGF alone, 20 ng/mL PDGF-AB alone, or a combination of cyclic strain with either growth factor for 12 hours.
Statistical Analysis
Results are mean±SEM. Statistical analysis between 2 groups was determined by a factorial ANOVA followed by the Fischer protected least significant difference test. Values of P<0.05 were considered significantly different.
| Results |
|---|
|
|
|---|
|
|
HASMC Proliferation in Response to Thrombin
The proliferation of static and cyclically strained HASMCs in response to thrombin was measured to determine the functional consequences of cyclic strain-induced PAR-1 expression. Compared with cell proliferation in static control cells, thrombin (5 U/mL) increased cell proliferation in HASMCs after exposure to 20% strain for 48 hours (P<0.05) but not in cells strained for 24 hours (Figure 3). Without thrombin stimulation, the cell number was not significantly different between cyclically strained and static cells at either time.
|
Role of ROS and NO Synthase in Strain-Induced PAR-1 Expression
Cyclic strain (20%) enhanced O2- production in a time-dependent manner, reaching the maximum after 60 minutes of exposure (Figure 4). Two antioxidants, NAC and PDTC, significantly inhibited strain-enhanced PAR-1 mRNA (Figure 5C), whereas neither NAC (Figure 5A) nor PDTC (data not shown) inhibited PAR-1 expression in static HASMCs. Furthermore, DPI, an NADPH oxidase inhibitor, significantly blocked strain-increased PAR-1 mRNA (Figure 5B), whereas inhibitors of xanthine oxidase (oxypurinol) and cyclooxygenase (indomethacin) had no significant effects (Figure 5C). Inhibiting NO synthases with L-NMMA showed no significant effect on the increase of PAR-1 mRNA by cyclic strain (Figure 5C).
|
|
Role of Protein Kinases in Strain-Induced PAR-1 Expression
Strain-increased PAR-1 mRNA was enhanced by the nonspecific protein kinase inhibitor staurosporine at all concentrations (Figure 6A and 6B) and by the specific PKC inhibitor Ro 31-8220 (Figure 6B, P<0.05). Neither herbimycin A (tyrosine kinase inhibitor) nor PD 098,095 (MAPK kinase inhibitor) had significant effects on strain-induced PAR-1 expression (Figure 6B). None of the inhibitors had significant effects on PAR-1 mRNA in static cells nor did the PKC activator PMA (data not shown).
|
Effects of Cyclic Strain and Growth Factors on PAR-1 Expression
Treatment of HASMCs with 20% strain, bFGF, or PDGF-AB alone caused a marked increase in PAR-1 mRNA compared with the control condition (Figure 7, P<0.05). Exposure of cells to 20% strain together with bFGF induced a 4-fold increase in PAR-1 mRNA compared with the effect of 20% strain or bFGF alone (Figure 7, P<0.05), indicating an additive effect of cyclic strain and bFGF on PAR-1 expression. Unlike treatment with bFGF, treatment of cells with 20% strain plus PDGF-AB did not significantly increase PAR-1 mRNA compared with treatment of cells with 20% strain or PDGF-AB alone.
|
| Discussion |
|---|
|
|
|---|
Cyclic strain increased PAR-1 mRNA and protein levels (Figures 1 and 2), and after 48 hours of cyclic strain, thrombin also produced a 50% increase in cell number (Figure 3). The significance of these findings is based on the opposite responses of PAR-1 expression to cyclic strain and shear stress. PAR-1 expression increases 2-fold under 20% cyclic strain for 24 hours, whereas it decreases by
4-fold under shear stress (25 dyne/cm2) for 24 hours.14 Thus, mechanical forces regulate the PAR-1 gene differently, depending on the balance of mechanical forces to which the cells are subjected over the cardiac cycle. These differences must be signaled through different pathways, or a critical on/off switch along a common pathway must play a role in producing opposing responses. Another possible explanation for differing directions of PAR-1 response is that the threshold of injury to cyclic strain might be lower than that to shear stress. Cyclic strain produces greater membrane perturbations than does shear stress. Cheng et al7 found that membrane disruption of SMCs occurred under 14% cyclic strain, 1 Hz, for 10 minutes, whereas Rhoads et al23 found less membrane disruption under 25 dyne/cm2 shear stress for 15 minutes by use of the same techniques (fluorescent dextran markers).
The observations that PAR-1 promoter regions contain antioxidant response element-like consensus sequences22 and that cyclic strain rapidly increases superoxide production17 suggest an important role of oxidant-mediated mechanisms in regulating PAR-1 expression in VSMCs. In the present study, cyclic strain stimulated superoxide production in VSMCs after a short exposure (Figure 4), in agreement with previous work,17 and antioxidants significantly inhibited strain-induced PAR-1 expression (Figure 5). Furthermore, strain-enhanced PAR-1 expression decreased after treatment of cells with the NADPH oxidase inhibitor DPI (Figure 5). Treatment of cells with the NO synthase inhibitor L-NMMA or the xanthine oxidase (oxypurinol) or cyclooxygenase (indomethacin) inhibitors showed no effect on strain-induced PAR-1 expression. This provides evidence that the PAR-1 response to cyclic strain is mediated by ROS in VSMCs through the NADPH oxidase pathway.
Besides ROS, protein kinases may act as second messengers for cyclic strain signaling. Our results with staurosporine and Ro 31-8220 were unexpected (Figure 6), with both inhibitors increasing expression at least 3-fold over stationary control levels rather than inhibiting cyclic strain-induced PAR-1 expression. Staurosporine is a nonselective PKC inhibitor (inhibiting protein kinase A, myosin light chain kinase, and phosphorylase kinase, among other enzymes), whereas Ro 31-8220 is a potent and selective inhibitor of PKC.24 The corroboration between the results obtained with Ro 31-8220 and staurosporine provides evidence that cyclic strain signaling is occurring through PKC.
Stimulatory responses of VSMC to staurosporine and Ro 31-8220 are not without precedent. Hecker et al25 noted that staurosporine "paradoxically" potentiated rather than inhibited interleukin-1ß-induced NO2- formation in VSMCs, whereas Ro 31-8220 downregulated NO2- production. NO2- formation is a reflection of inducible NO synthase mRNA synthesis. They suggest that an unidentified PKC plays a role in the negative control of the inducible NO synthase gene expression or that there is a protein kinase that prevents inducible NO synthase gene expression. Fisslthaler et al19 found that angiotensin II increases PAR-1 mRNA 3-fold. Administering staurosporine or Ro 31-8220 (at the same concentrations used in the present study) enhanced angiotensin II-stimulated PAR-1 expression, suggesting that PKC negatively regulates the signaling of the angiotensin II-stimulated increase in PAR-1 expression. Mills et al26 found no effect of up to 20 ng/mL staurosporine on cyclic strain-increased proliferation of bovine aortic smooth muscle cells. Hishikawa et al17 found that treatment with the PKC inhibitor chelerythrine significantly inhibited cyclic strain O2- production in VSMCs.
It is tempting to speculate that the synergistic effect of PKC inhibitors on cyclic strain-induced PAR-1 gene expression that we find, which is consistent with the effects of staurosporine and Ro 31-8220 found by others,19 might be based on upregulation of apoptosis-associated signaling pathways. The concentrations of staurosporine used to induce apoptosis are 3 orders of magnitude higher than those used to inhibit protein kinase signaling pathways, but perhaps VSMCs are more sensitive to modulation of these pathways. Rat VSMCs respond to oxidative stress by undergoing apoptosis, and PKC has a central role in signaling this. PKC switches H2O2-induced death in these cells from necrosis to apoptosis. PKC activation in these VSMCs was inhibited by 50 nmol/L staurosporine in the rat VSMCs,20 whereas we found augmentation of the cyclic strain-induced PAR-1 increase with 20 nmol/L staurosporine.
Inhibitors of tyrosine kinase (herbimycin A) and MAPK kinase (PD 098,059) had no effect on the cyclic strain-induced increase in PAR-1 expression in the present study (Figure 6). However, cyclic strain has been shown to signal through tyrosine kinase in stimulating monocyte chemotactic protein-1 in VSMCs.27 In addition, a MAPK pathway mediates strain-increased MAPK phosphatase-1 expression in VSMCs.20 Cyclic strain increases the activation of PKC26 and MAPK,28 thus suggesting that these signaling elements may be involved in cyclic strain-regulated VSMC responses.
Treatment of cells with the PKC activator PMA had no effect on PAR-1 expression. It is possible that PMA-insensitive isoforms of PKC are involved in cyclic strain-induced PAR-1 expression, because some PKC isoforms, such as PKC-
, do not bind diacylglycerol or phorbol esters.29,30
Because PAR-1 expression is induced by growth factors in addition to cyclic strain,21 it is possible that cyclic strain acts together with growth factors released from platelets and vascular cells to alter gene expression maintaining VSMCs in a proliferative state. Aggregating platelets have been shown to induce thrombin receptor expression in cultured VSMCs through the release of transforming growth factor-ß1 and PDGF-AB.13 In vascular cells, the growth-promoting effects of hemodynamic forces increase the release of growth factors, such as PDGF31 and bFGF,23 which also enhances the expression of PAR-1.12 This additive effect of cyclic strain and bFGF on PAR-1 expression (Figure 7) suggests that cyclic strain and bFGF may cooperatively promote mitogenesis of VSMCs in response to thrombin.
Although one must appreciate the fact that results obtained with cultured cells are questionably relevant to in vivo events, in vitro findings, such as those in the present study, provide investigative tools that will lead to more relevant in vivo models for cardiovascular diseases.
In summary, we have demonstrated that cyclic strain induces the expression of PAR-1, leading to the increase of VSMC proliferation in response to thrombin. The cyclic strain-increased PAR-1 expression may be mediated via ROS and PKC signaling pathways. Because PAR-1 expression in VSMCs mediates many effects of thrombin on the blood vessel wall, an understanding of the PAR-1 gene regulation by the mechanical forces of cyclic strain and shear stress may offer insight into vascular proliferative diseases.
| Acknowledgments |
|---|
Received March 13, 2001; first decision April 2, 2001; accepted April 11, 2001.
| References |
|---|
|
|
|---|
B in human coronary smooth muscle. Circ Res. 1997; 81: 797803.This article has been cited by other articles:
![]() |
A. L. Pyle, J. B. Atkinson, A. Pozzi, J. Reese, B. Eckes, J. M. Davidson, D. L. Crimmins, and P. P. Young Regulation of the Atheroma-Enriched Protein, SPRR3, in Vascular Smooth Muscle Cells through Cyclic Strain is Dependent on Integrin {alpha}1{beta}1/Collagen Interaction Am. J. Pathol., November 1, 2008; 173(5): 1577 - 1588. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hirano The Roles of Proteinase-Activated Receptors in the Vascular Physiology and Pathophysiology Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 27 - 36. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Chapman, S. E. Sinclair, D. Zhuang, A. Hassid, L. P. Desai, and C. M. Waters Cyclic mechanical strain increases reactive oxygen species production in pulmonary epithelial cells Am J Physiol Lung Cell Mol Physiol, November 1, 2005; 289(5): L834 - L841. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Frye, A. Yee, S. G. Eskin, R. Guerra, X. Cong, and L. V. McIntire cDNA microarray analysis of endothelial cells subjected to cyclic mechanical strain: importance of motion control Physiol Genomics, March 21, 2005; 21(1): 124 - 130. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Steinhoff, J. Buddenkotte, V. Shpacovitch, A. Rattenholl, C. Moormann, N. Vergnolle, T. A. Luger, and M. D. Hollenberg Proteinase-Activated Receptors: Transducers of Proteinase-Mediated Signaling in Inflammation and Immune Response Endocr. Rev., February 1, 2005; 26(1): 1 - 43. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Cowan, M. Jones, L. M. Garcia, S. Noria, P. J. del Nido, and F. X. McGowan Jr Hypoxia and Stretch Regulate Intercellular Communication in Vascular Smooth Muscle Cells Through Reactive Oxygen Species Formation Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1754 - 1760. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. G. Birukov, J. R. Jacobson, A. A. Flores, S. Q. Ye, A. A. Birukova, A. D. Verin, and J. G. N. Garcia Magnitude-dependent regulation of pulmonary endothelial cell barrier function by cyclic stretch Am J Physiol Lung Cell Mol Physiol, October 1, 2003; 285(4): L785 - L797. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Goldman, L. Zhong, and S. Q. Liu Degradation of alpha -actin filaments in venous smooth muscle cells in response to mechanical stretch Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1839 - H1847. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |